Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE,…
Fobi AI Responds To CTO (Cease Trade Order) Commitment To Financial Transparency and Audit Completion
November 01, 2024 19:41 ET | Source: Fobi AI Inc. VANCOUVER, BC,…